Cargando…

Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis

BACKGROUND: Current treatments for idiopathic inflammatory myopathies (collectively called myositis) focus on the suppression of an autoimmune inflammatory response within the skeletal muscle. However, it has been observed that there is a poor correlation between the successful suppression of muscle...

Descripción completa

Detalles Bibliográficos
Autores principales: Coley, William, Rayavarapu, Sree, van der Meulen, Jack H., Duba, Ayyappa S., Nagaraju, Kanneboyina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681851/
https://www.ncbi.nlm.nih.gov/pubmed/23785461
http://dx.doi.org/10.1371/journal.pone.0065970
_version_ 1782273328924327936
author Coley, William
Rayavarapu, Sree
van der Meulen, Jack H.
Duba, Ayyappa S.
Nagaraju, Kanneboyina
author_facet Coley, William
Rayavarapu, Sree
van der Meulen, Jack H.
Duba, Ayyappa S.
Nagaraju, Kanneboyina
author_sort Coley, William
collection PubMed
description BACKGROUND: Current treatments for idiopathic inflammatory myopathies (collectively called myositis) focus on the suppression of an autoimmune inflammatory response within the skeletal muscle. However, it has been observed that there is a poor correlation between the successful suppression of muscle inflammation and an improvement in muscle function. Some evidence in the literature suggests that metabolic abnormalities in the skeletal muscle underlie the weakness that continues despite successful immunosuppression. We have previously shown that decreased expression of a purine nucleotide cycle enzyme, adenosine monophosphate deaminase (AMPD1), leads to muscle weakness in a mouse model of myositis and may provide a mechanistic basis for muscle weakness. One of the downstream metabolites of this pathway, D-ribose, has been reported to alleviate symptoms of myalgia in patients with a congenital loss of AMPD1. Therefore, we hypothesized that supplementing exogenous D-ribose would improve muscle function in the mouse model of myositis. We treated normal and myositis mice with daily doses of D-ribose (4 mg/kg) over a 6-week time period and assessed its effects using a battery of behavioral, functional, histological and molecular measures. RESULTS: Treatment with D-ribose was found to have no statistically significant effects on body weight, grip strength, open field behavioral activity, maximal and specific forces of EDL, soleus muscles, or histological features. Histological and gene expression analysis indicated that muscle tissues remained inflamed despite treatment. Gene expression analysis also suggested that low levels of the ribokinase enzyme in the skeletal muscle might prevent skeletal muscle tissue from effectively utilizing D-ribose. CONCLUSIONS: Treatment with daily oral doses of D-ribose showed no significant effect on either disease progression or muscle function in the mouse model of myositis.
format Online
Article
Text
id pubmed-3681851
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36818512013-06-19 Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis Coley, William Rayavarapu, Sree van der Meulen, Jack H. Duba, Ayyappa S. Nagaraju, Kanneboyina PLoS One Research Article BACKGROUND: Current treatments for idiopathic inflammatory myopathies (collectively called myositis) focus on the suppression of an autoimmune inflammatory response within the skeletal muscle. However, it has been observed that there is a poor correlation between the successful suppression of muscle inflammation and an improvement in muscle function. Some evidence in the literature suggests that metabolic abnormalities in the skeletal muscle underlie the weakness that continues despite successful immunosuppression. We have previously shown that decreased expression of a purine nucleotide cycle enzyme, adenosine monophosphate deaminase (AMPD1), leads to muscle weakness in a mouse model of myositis and may provide a mechanistic basis for muscle weakness. One of the downstream metabolites of this pathway, D-ribose, has been reported to alleviate symptoms of myalgia in patients with a congenital loss of AMPD1. Therefore, we hypothesized that supplementing exogenous D-ribose would improve muscle function in the mouse model of myositis. We treated normal and myositis mice with daily doses of D-ribose (4 mg/kg) over a 6-week time period and assessed its effects using a battery of behavioral, functional, histological and molecular measures. RESULTS: Treatment with D-ribose was found to have no statistically significant effects on body weight, grip strength, open field behavioral activity, maximal and specific forces of EDL, soleus muscles, or histological features. Histological and gene expression analysis indicated that muscle tissues remained inflamed despite treatment. Gene expression analysis also suggested that low levels of the ribokinase enzyme in the skeletal muscle might prevent skeletal muscle tissue from effectively utilizing D-ribose. CONCLUSIONS: Treatment with daily oral doses of D-ribose showed no significant effect on either disease progression or muscle function in the mouse model of myositis. Public Library of Science 2013-06-13 /pmc/articles/PMC3681851/ /pubmed/23785461 http://dx.doi.org/10.1371/journal.pone.0065970 Text en © 2013 Coley et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Coley, William
Rayavarapu, Sree
van der Meulen, Jack H.
Duba, Ayyappa S.
Nagaraju, Kanneboyina
Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title_full Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title_fullStr Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title_full_unstemmed Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title_short Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
title_sort daily supplementation of d-ribose shows no therapeutic benefits in the mhc-i transgenic mouse model of inflammatory myositis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681851/
https://www.ncbi.nlm.nih.gov/pubmed/23785461
http://dx.doi.org/10.1371/journal.pone.0065970
work_keys_str_mv AT coleywilliam dailysupplementationofdriboseshowsnotherapeuticbenefitsinthemhcitransgenicmousemodelofinflammatorymyositis
AT rayavarapusree dailysupplementationofdriboseshowsnotherapeuticbenefitsinthemhcitransgenicmousemodelofinflammatorymyositis
AT vandermeulenjackh dailysupplementationofdriboseshowsnotherapeuticbenefitsinthemhcitransgenicmousemodelofinflammatorymyositis
AT dubaayyappas dailysupplementationofdriboseshowsnotherapeuticbenefitsinthemhcitransgenicmousemodelofinflammatorymyositis
AT nagarajukanneboyina dailysupplementationofdriboseshowsnotherapeuticbenefitsinthemhcitransgenicmousemodelofinflammatorymyositis